))
Old Drugs, New Tricks: Putting an End to Traditional Eye Drops
Archived series ("HTTP Redirect" status)
Replaced by: Carnegie Science Center Podcast
When?
This feed was archived on January 04, 2018 22:39 (
Why? HTTP Redirect status. The feed permanently redirected to another series.
What now? If you were subscribed to this series when it was replaced, you will now be subscribed to the replacement series. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 194513848 series 1876051
Content provided by Carnegie Science Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Carnegie Science Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Old Drugs, New Tricks: Putting an End to Traditional Eye Drops Presenter:
…
continue reading
Morgan Fedorchak
Director
Ophthalmic Biomaterials Laboratory
Glaucoma is the second leading cause of blindness worldwide, expected to affect up to 3 million Americans by 2020. One of the main risk factors in glaucoma is an unsafe increase in intraocular pressure (IOP). IOP reduction in patients with glaucoma is typically accomplished through the administration of medicated eye drops several times daily, the difficult and frequent nature of which contributes to patient adherence rates estimated to be as low as 30%. Newer drug delivery methods for glaucoma aimed at improving patient adherence require clinician administration of invasive injections or implants. This talk will encompass the rational design and testing of a variety of controlled release systems for delivery of ocular drugs as well as the many significant considerations for translating these technologies to the clinic where they may benefit patients. In particular, discussion will focus on our team’s development of a completely unique formulation that provides one month of therapeutic levels of glaucoma medication from a noninvasive eye drop. We believe that this new treatment method may have the ability to overcome the issues inherent to traditional eye drop medication while avoiding the need for more invasive techniques.
Morgan Fedorchak is an Assistant Professor of Ophthalmology, Chemical Engineering, and Clinical and Translational Science at the University of Pittsburgh and the director of the Ophthalmic Biomaterials Laboratory. She attended Carnegie Mellon University where she obtained her B.S. in both Chemical Engineering and Biomedical Engineering in 2006. She later earned her PhD in bioengineering at the University of Pittsburgh in 2011 under Dr. William Federspiel studying hemofiltration and medical devices. Subsequently, she was awarded a fellowship from the Fox Center for Vision Restoration to participate in a collaboration between Dr. Steve Little and Dr. Joel Schuman as a postdoctoral researcher in March of 2011. This work formed the basis for the development of a patent pending drug delivery system for glaucoma that was recently featured in The Wall Street Journal. Her research is currently supported by the National Eye Institute, the Cystinosis Research Foundation, the University of Pittsburgh Center for Medical Innovation, and the Wallace H. Coulter Foundation.
Recorded Monday, September 12, 2016 at Carnegie Science Center in Pittsburgh, PA.
20 episodes
Share
